Molecule Information

General Information of the Molecule (ID: Mol05623)

• Name: SNAI3-AS1 ,Homo sapiens
• Molecule Type: Long non-coding RNA
• Sequence:
  CGGCGATCCGGGGTCTGGGCGCGGCGAGGTCTGGTGTGGCAGATGTGGATAGCTGGACCC
  TCCTGGGTGCCTCTGCGTTATGTCGTTTGGTTGATGCATTTGGAGAGAATCTGTGCTCTC
  CACAACTGCAGGGGCAACATGCTTTCCTGGCCTCTTCAGATCAGGGTGGCTGTTCTTGGG
  TGCTGCACCAAAACTCCAGCAGTGGGCTTTCTTCAAGTGGCCGGCTCACCTCATTCCTGC
  CAAGACCCAGGTCCGTGTTCTCACAGTGCTGCCATCTTTCCTCCGTGTGAGCGTGGGCTG
  TGCGGAGAGTGGACCTCGGTGTGTGCGGGGCTGCGTGCACTGCCATCGCTCCCTCTACAC
  GAGCCGGCGTGGACCCAGGGCTGAGCTGTGACCACGAGGGCCATCCCGACGAGCCGCCAT
  GGACCCAGGGCTGAGCTGTGACCATGAGGGCTATCCCGACGAGCTGCCGTGGACCCAGGG
  CTGAGCCGTGACCATGAGGGCCATCCCGAAACTGTGATTGTTTTCTGAATGTGGAAGCGT
  CGGCCGAGCGCGGTCCTTGGAGAACCCTTGCTGCGGAGAATGACGCTCACTCTGCGGCCT
  GGCCTCGCCTCCCCATCCCTTCTGCAAACTCACAGGACAGGATTGATGGGGAGAGCCCAG
  GCGAAACGAAGCTGACCCTAGTGACCAGCCCTACTGGCGGCTCTGGAACAGGCCCGGGAC
  CGGTGGCCTGGAGACAGTGGTCCTTTCTGGATGGGCTGCAGTCTCCGAAGGCTTCCCCCA
  CTGGAGTCAGCCCTTTAGGAGTTTGTCCAGTGCCTCCAGAAAGCTGTTTTTTGGGGGACG
  GAGGACTTGGCCTGGAATTCTGGAATTCCCAGGGGGTCAGACATGGTTATGGGAAGTTTA
  ATAAAACCGGTGAATCACGTGAAAAAAAAAAAAAAAAAAAAA

Kingdom: Metazoa
Phylum: Chordata
Class: Mammalia
Order: Primates
Family: Hominidae
Genus: Homo
Species: Homo sapiens

Type(s) of Resistant Mechanism of This Molecule

  EADR: Epigenetic Alteration of DNA, RNA or Protein

Drug Resistance Data Categorized by Drug

Approved Drug(s) 1 drug(s) in total

Temozolomide

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Disease Class: Glioma [ICD-11: 2A00.02] [1]

• Resistant Disease: Glioma [ICD-11: 2A00.02]
• Resistant Drug: Temozolomide
• Molecule Alteration: Expression; Down-regulation
• Experimental Note: Revealed Based on the Cell Line Data
• Cell Pathway Regulation: SNAI3-AS1/SND1/Nrf2 signalling axis; Regulation; N.A.
• In Vitro Model: U87MG cells; Brain; Homo sapiens (Human); CVCL_GP63
• In Vitro Model: U251 cells; Brain; Homo sapiens (Human); CVCL_0021
• In Vitro Model: A172 cells; Brain; Homo sapiens (Human); CVCL_0131
• In Vitro Model: LN229 cells; Brain; Homo sapiens (Human); CVCL_0393
• In Vitro Model: U373 cells; Brain; Homo sapiens (Human); CVCL_2219
• In Vitro Model: T98G cells; Brain; Homo sapiens (Human); CVCL_0556
• In Vivo Model: Glioma patients; Nude mouse xenograft model; Homo sapiens
• Experiment for Molecule Alteration: RT-qPCR; Bisulfite sequencing PCR; Western blotting; RNA pull-down; RIP assays; Immunofluorescence; Immunohistochemistry; Dual-luciferase reporter assays; mRNA stability assays
• Experiment for Drug Resistance: Cell viability assays;Ccolony formation assays; EdU assays; Cell migration assays; Cell invasion assays; Cell cycle assays; Iron assays; Lipid ROS assays
• Mechanism Description: We found that ferroptosis inducer erastin downregulates SNAI3-AS1 expression in glioma by increasing the DNA methylation level of SNAI3-AS1 promoter. SNAI3-AS1 functions as a tumor suppressor in glioma. Importantly, SNAI3-AS1 enhances the anti-tumor activity of erastin by promoting ferroptosis both in vitro and in vivo. Mechanistically, SNAI3-AS1 competitively binds to SND1 and perturbs the m6A-dependent recognition of Nrf2 mRNA 3'UTR by SND1, thereby reducing the mRNA stability of Nrf2. Rescue experiments confirmed that SND1 overexpression and silence can rescue the gain- and loss-of-function ferroptotic phenotypes of SNAI3-AS1, respectively.

References

• Ref 1: Indian J Med Paediatr Oncol. 2015 Apr-Jun;36(2):133-6. doi: 10.4103/0971-5851.158852.